QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data
MWN-AI** Summary
Hagens Berman, a national shareholder rights law firm, has announced an investigation into uniQure N.V. (NASDAQ: QURE) following recent critical statements from the FDA regarding the accuracy and integrity of data presented by the company. This inquiry is linked to a class-action lawsuit for investors who acquired uniQure shares between September 24 and October 31, 2025. Investors are reminded that there is a deadline of April 13, 2026, for lead plaintiff applications in this case.
In a recent media briefing, an FDA official criticized uniQure's lead gene therapy candidate, AMT-130, labeling it a "failed therapy" and alleging that the company was presenting a "distorted or manipulated comparison" in clinical studies. The FDA has raised concerns about the ethical implications of required sham surgeries and denied any prior agreement regarding their methodology. Specifically, the official clarified that the agency’s requirement was mischaracterized, indicating they had not requested invasive procedures as described by uniQure.
The class action complaint, titled *Scocco v. uniQure N.V.*, alleges that uniQure misrepresented its regulatory interactions and relied on unapproved study designs. Key accusations include the failure to disclose the FDA’s lack of consensus about using external historical data as a primary control and downplaying the need for a control arm in clinical trials.
As the situation unfolds, investors who may have suffered losses are encouraged to investigate their rights, especially as the deadline for submitting lead plaintiff motions approaches quickly. For anyone with additional information about uniQure's practices, Hagens Berman has opened channels for potential whistleblowers to contribute insights.
MWN-AI** Analysis
The recent turbulence surrounding uniQure N.V. (NASDAQ: QURE) poses significant concerns for stakeholders as the company grapples with serious allegations from the FDA regarding the integrity of its clinical data, particularly related to its gene therapy candidate, AMT-130. The FDA's public rebuke, labeling the treatment as a “failed therapy” and claiming that uniQure presented distorted data comparisons, raises red flags about both the product’s viability and the company’s transparency.
As a financial analyst, it is critical to recognize the associated risks in holding QURE shares at this juncture. The ongoing investigation and the pending securities class action lawsuit initiated by Hagens Berman could lead to further declines in stock value, especially with the next critical deadline approaching on April 13, 2026. Investors should be cautious, as the legal ramifications could not only affect share price adversely but also impact public perception and future investor interest.
Moreover, the FDA’s strong pushback against uniQure’s claims and its insistence on the necessity of a sham-controlled surgery arm indicates regulatory challenges that the company may struggle to overcome. This lack of clarity on regulatory consensus might complicate the path to any future applications for a Biologics License, further aggravating investor uncertainty.
Given these factors, it may be prudent for investors to either reassess their exposure to uniQure or consider alternative investment opportunities within the biotech sector that may present less volatile conditions. Monitoring the developments surrounding the litigation and FDA communications will be critical; a more definitive approach should be taken as new information unfolds regarding uniQure’s strategies and the ability to pivot in light of these allegations.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Suit
SAN FRANCISCO, March 20, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025 (the "Class Period"). The firm reminds investors of the April 13, 2026, Lead Plaintiff deadline in the pending securities class action.
SUBMIT YOUR QURE LOSSES TO HBSS NOW
The FDA Clash: "A Distorted or Manipulated Comparison"
On March 5 and 6, 2026, media outlets including The Wall Street Journal, CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.
The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the mind of FDA" instead of running a correct clinical study.
Key revelations from the March 6 disclosure include:
- Sham Surgery Mischaracterization: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, accusing the company of mischaracterizing the agency's request. The official clarified that the FDA did not ask to "drill holes in skulls," but rather required "one to three nicks in the scalp" under minimal anesthesia.
- Denial of Prior Agreement: While uniQure CEO Matt Kapusta described the sham surgery requirement as a "drastic change" from previous guidance, the FDA official pushed back, stating the agency "never agreed to accept this distorted comparison" using natural history as a comparator.
- Ineligibility for "Plausible Mechanism" Pathway: The official disputed AMT-130's eligibility for streamlined rare-disease pathways, noting it is not an individualized treatment.
The recent reports follow the filing of a securities class action suit.
Investors in uniQure (QURE) are encouraged to visit the Hagens Berman QURE Case Page to review the allegations in the pending litigation: www.hbsslaw.com/cases/uniqure
"The pending securities class action alleges a consistent pattern: that uniQure misrepresented its interactions with the FDA and used a pivotal study design that it knew the agency had not approved," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the alleged claim in the pending litigation.
Summary of QURE Class Action Allegations: The "Pivotal" Study Mirage
The securities class action, Scocco v. uniQure N.V., et al. (S.D.N.Y.), alleges that throughout the Class Period (Sept. 24, 2025 – Oct. 31, 2025), defendants failed to disclose:
- No Regulatory Consensus: That the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130.
- Hidden Requirements: That uniQure downplayed the necessity of a sham-controlled surgery arm for Phase III—a requirement the FDA now claims was never waived.
- Timeline Deception: That defendants misled investors regarding the timing of a Biologics License Application (BLA), which was rendered "unclear" once the lack of FDA agreement was revealed on November 3, 2025, sending the stock down 49%.
Critical Deadline: April 21, 2026
If you purchased uniQure ordinary shares during the Class Period (Sept. 24, 2025 – Oct. 31, 2025) and suffered losses, you have until April 13, 2026, to ask the Court to appoint you as Lead Plaintiff.
- Submit Your QURE Losses to HBSS Now
- Contact: Reed Kathrein at 844-916-0895 or email QURE@hbsslaw.com
If you'd like more information and answers to additional frequently asked questions about the uniQure case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding uniQure should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email QURE@hbslaw.com.
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
SOURCE Hagens Berman Sobol Shapiro LLP
FAQ**
What specific misrepresentations did uniQure N.V. QURE allegedly make regarding its interactions and agreements with the FDA throughout the Class Period?
How might the recent FDA criticisms affect the future clinical trials and market potential of uniQure N.V. QURE's lead gene therapy candidate, AMT-130?
What potential implications does the ongoing securities class action hold for investors in uniQure N.V. QURE, particularly in terms of financial restitution?
In light of the FDA's rebuke, what steps is uniQure N.V. QURE planning to take to rectify its standing with regulatory bodies and regain investor confidence?
**MWN-AI FAQ is based on asking OpenAI questions about uniQure N.V. (NASDAQ: QURE).
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
